These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


807 related items for PubMed ID: 2539648

  • 1. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 2. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Antonio S, Isidori P, Gasparini S.
    Anticancer Res; 1994 Feb; 14(5B):2221-7. PubMed ID: 7840527
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 5. [Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer].
    Miyamoto H, Kawakami Y, Arimoto T, Asakawa M, Suzuki A, Fujikane T, Onodera S, Nakabayashi T, Yasuda S, Shimizu T.
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1127-34. PubMed ID: 1647149
    [Abstract] [Full Text] [Related]

  • 6. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R.
    Anticancer Res; 1991 Jun; 11(2):681-4. PubMed ID: 1648333
    [Abstract] [Full Text] [Related]

  • 7. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M, Ochi Y, Kadota A, Akusawa H, Kisohara A, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 2000 Jun; 7(2):305-10. PubMed ID: 10671676
    [Abstract] [Full Text] [Related]

  • 8. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
    Ohnoshi T, Hiraki S, Ueoka H, Kawahara S, Numata T, Nishii K, Yonei T, Yamashta H, Kiura K, Kozuka A.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S, Segawa Y, Harada M.
    Cancer; 1998 Jul 15; 83(2):283-90. PubMed ID: 9669811
    [Abstract] [Full Text] [Related]

  • 10. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A, Ueoka H, Kiura K, Tabata M, Sunami K, Katayama Y, Yamane H, Hiraki A, Harada M.
    Anticancer Res; 1999 Jul 15; 19(1B):693-8. PubMed ID: 10216478
    [Abstract] [Full Text] [Related]

  • 11. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 15; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 12. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.
    Jpn J Clin Oncol; 1994 Oct 15; 24(5):275-81. PubMed ID: 7967106
    [Abstract] [Full Text] [Related]

  • 13. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N, Takada M, Negoro S, Ota K, Fujita J, Furuse K, Ariyoshi Y, Ikegami H, Fukuoka M.
    Cancer; 1996 Jan 01; 77(1):63-70. PubMed ID: 8630941
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 01; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 15. [Chemotherapy of small cell lung cancer].
    Fukuoka M, Negoro S, Takada M, Kusunoki Y, Matsui K, Ryu S, Sakai N, Yamamoto H, Masuda N, Takifuji N.
    Gan To Kagaku Ryoho; 1988 Apr 01; 15(4 Pt 2-1):966-72. PubMed ID: 2839116
    [Abstract] [Full Text] [Related]

  • 16. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
    Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R.
    Semin Oncol; 1994 Jun 01; 21(3 Suppl 6):31-5. PubMed ID: 8052871
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A, Georgoulias V.
    Lung Cancer; 2006 Jul 01; 53(1):59-65. PubMed ID: 16716447
    [Abstract] [Full Text] [Related]

  • 18. The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
    Ettinger DS.
    Semin Oncol; 1995 Feb 01; 22(1 Suppl 2):23-7. PubMed ID: 7846538
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 20. Alternating chemotherapy with cyclophosphamide/adriamycin/vincristine (CAV) and cisplatin/etoposide (PVP) against small cell lung cancer. Eastern Shikoku Lung Cancer Chemotherapy Group.
    Bando H, Takishita Y, Ogura T, Sone S, Shimizu E, Nakayama T, Doi H, Kobayashi M.
    Jpn J Clin Oncol; 1991 Dec 15; 21(6):435-9. PubMed ID: 1666660
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 41.